- Trial Phase
- Phase 3
- Time to Market
- At least 2-3 years; Phase 3 trials recently initiated, and assuming positive data, a BLA submission would likely follow in late 2028-2029.
- Why 5/10
- Rezpegaldesleukin is Nektar's lead asset and essentially the entire value driver, but there is no single hard dated binary (PDUFA or pivotal topline readout) within the next ~12 months — Phase 3 trials were only recently initiated. The next catalysts are data updates, which are important but not imminent binary events, so the score is capped at 5.
Investors should watch for Phase 3 topline data readouts for rezpegaldesleukin in atopic dermatitis and alopecia areata (likely H2 2027 to 2028). The stock is heavily shorted (~18.65% of shares outstanding as of July 31, 2026) — any positive Phase 3 data could trigger significant upside. Monitor the ~18% diluted share count increase from recent offerings and watch for further ATM sales. Current price offers ~107% upside to the mean analyst target of ~$153.
Price Chart
Executive Summary
Rezpegaldesleukin (NKTR-358) is Nektar Therapeutics' lead pipeline asset — an engineered IL-2 fusion protein designed to selectively expand regulatory T cells (Tregs) to treat autoimmune diseases by re-establishing immune tolerance. It has been granted FDA Fast Track designation for both moderate-to-severe atopic dermatitis and severe alopecia areata. Nektar initiated Phase 3 trials for atopic dermatitis in Q2 2026 following positive Phase 2b data in alopecia areata. With $1.02B in cash (runway into Q3 2028), strong institutional backing from FMR, BlackRock, and Vanguard, and a consensus analyst price target of ~$153 (more than double the current ~$74 stock price), rezpegaldesleukin represents a high-conviction binary catalyst for Nektar over the next 12-18 months.
How It Works
Rezpegaldesleukin is an engineered version of interleukin-2 (IL-2), a naturally occurring immune-signaling protein. Unlike standard IL-2, which broadly activates immune cells, this drug is designed to preferentially expand regulatory T cells (Tregs) — the immune system's "peacekeepers" that calm excessive inflammation. By boosting Tregs without overstimulating other immune cells, it aims to re-establish immune tolerance in autoimmune diseases like atopic dermatitis (eczema) and alopecia areata (patchy hair loss).
Trial Status
Phase 3 trials initiated in moderate-to-severe atopic dermatitis as of Q2 2026. Positive Phase 2b data generated in severe alopecia areata (enabled a $325M follow-on offering in April 2026). FDA Fast Track designation granted for both indications (Feb 2025 for atopic dermatitis, July 2025 for alopecia areata). Company also advancing NKTR-255 in oncology.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 topline data readout(s) for rezpegaldesleukin in atopic dermatitis (likely H2 2027 or later)
- Phase 2/3 data updates in alopecia areata
- Potential partnership / out-licensing for ex-US rights
- Quarterly earnings reports with updates on enrollment and trial execution
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Nektar Therapeutics PRESS-RELEASE NKTR ·Originating report